摘要
目的观察吉非替尼一线治疗晚期非小细胞肺癌临床疗效及毒副作用。方法研究2005年11月～2007年5月14例晚期非小细胞肺癌患者,PS≥2,一线口服吉非替尼治疗,250mg/日,观察其近期疗效及毒副作用。结果14例患者中CR 0%(0/ 14),PR 35.7%(5/14),SD 50%(7/14),PD 14.3%(2/14)。临床获益率85.7% (12/14)。毒副作用为唑疮样皮疹42.86%(6/14),皮肤干燥脱屑28.57%(4/14),皮肤瘙痒14.3%(2/14),腹泻35.7(5/14),转氨酶升高14.3%(2/14)。结论吉非替尼一线治疗晚期非小细胞肺癌疗效较好,毒副作用轻微,能明显改善患者的生活质量。
Objective To evaluate the response and the side effects of gefitinib as the first-line treatment in patients with advanced non-small cell lung cancer. Methods Totally 14 non - small cell lung cancer patients with PS ≥2, treated from November 2005 to May 2007, were enrolled in our study Gefitinib was prescribed on the first lineat an oral dose of 250mg daily. The treatment response and side-effects were recorded. Results CR, PR, SD, PD were achived 0% （0/14）, 35.7% （5/14）, 50% （7/14）, and 14. 3% （2/14）, respectively. Symptom improvement was reported by 85.7% （12/14）. Adverse events included acneiform rash （6/14）, dry skin （4/14）, itching of skin （2/14）, diarrhea （5/14）, and hepatic dysfunction （2/14）. Conclusion Gefitinib is an effective first-line therapy for patients with advanced non-small cell lung cancer with acceptable side effects.
出处
《癌症进展》
2007年第6期589-592,601,共5页
Oncology Progress
